Table 5.
Summary of response rates of anti-hormonal therapy for aGCT.
| Regimen | Number of Regimens | CR n (%) |
PR n (%) |
SD n (%) |
PD n (%) |
Unknown n (%) |
|---|---|---|---|---|---|---|
| Aromatase inhibitor | 16 | 1 (6) | 5 (31) | 7 (44) | 3 (19) | 0 (0) |
| GnRH agonist | 9 | 0 (0) | 2 (22) | 6 (67) | 1 (11) | 0 (0) |
| Progestin | 6 | 0 (0) | 0 (0) | 5 (83) | 1 (17) | 0 (0) |
| SERM | 5 | 0 (0) | 0 (0) | 2 (40) | 3 (60) | 0 (0) |
| Combinations | 2 | 1 (50) | 0 (0) | 1 (50) | 0 (0) | 0 (0) |
| Type unknown | 44 | 1 (3) | 5 (11) | 21 (48) | 12 (27) | 5 (11) 1 |
| Total | 82 | 3 (4) | 12 (15) | 42 (51) | 20 (24) | 5 (6) |
1 For the remaining five patients, one was lost to follow-up, two were within the first 6 months of treatment and two did not tolerate treatment. CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, GnRH: gonadotropin-releasing hormone, SERM: selective estrogen receptor modulator.